Referência de medicamentos
Ponatinib
Ponatinib is a medicine in the class oncology. It is used for acute lymphocytic leukemia.
- Classe do medicamento: Oncology
- Indicado para: acute lymphocytic leukemia
Última atualização Fontes: US FDA label
Para profissionais de saúde — apenas referência. Esta página é um resumo breve, não é aconselhamento médico nem substitui a bula oficial ou o julgamento clínico. Verifique sempre antes de prescrever ou dispensar.
O conteúdo clínico desta página está disponível apenas em inglês.
Pontos-chave
- Classe do medicamento
- Oncology
- Código ATC
- L01EA05
- Formas farmacêuticas comuns
- comprimido
- Concentrações comuns
- 15 mg
- Interações conhecidas
- 114 (Grave: 18 · Moderada: 60 · Leve: 36)
- Nomes comerciais
- 3
- Países e mercados
- 3
Para que é usado
Como funciona
Ponatinib is a kinase inhibitor that inhibits ABL and T315I mutant ABL tyrosine kinase activity in vitro, and also inhibits VEGFR, PDGFR, FGFR, EPH receptor and SRC family kinases, KIT, RET, TIE2 and FLT3.
Dose habitual em adultos (resumo da bula)
Newly diagnosed Ph+ ALL: 30 mg orally once daily with chemotherapy; reduce to 15 mg once daily on MRD-negative CR at end of induction; continue up to 20 cycles until loss of response or unacceptable toxicity
Gravidez e amamentação
- Gravidez
- Unsafe Can cause fetal harm: no human data; in rats it caused developmental toxicity below human exposure. Avoid in pregnancy; check pregnancy status before starting and use effective contraception during treatment and for 3 weeks after.
- Amamentação
- Unsafe No milk data; it is over 99% protein bound, but its 24-hour half-life may allow build-up in the infant (LactMed). Do not breastfeed during treatment and for 1 week after the last dose (US label); NCCN also advises avoiding breastfeeding.
Efeitos adversos relatados
- Rash and related conditions
- Arthralgia
- Abdominal pain
- Fatigue
- Headache
- Constipation
Advertências de caixa preta
- Arterial occlusive events, including fatal MI, stroke, large cerebral artery stenosis and severe peripheral vascular disease, occurred, including in patients age 50 years or younger and without cardiovascular risk factors. Venous thromboembolic events, heart failure (including fatalities) and hepatotoxicity (liver failure and death) have occurred. Monitor, and interrupt or discontinue based on severity.
Quem deve ter cuidado
- Hypertension: monitor blood pressure and manage; interrupt, reduce or stop if not controlled.
- Pancreatitis: monitor serum lipase.
- Myelosuppression: CBC every 2 weeks for first 3 months, then monthly or as indicated.
Informe ao farmacêutico ou ao médico sobre gravidez ou amamentação, doença renal ou hepática, alergias e todos os outros medicamentos ou suplementos que você usa.
Principais interações (114)
- Apalutamide + Ponatinib Major
- Carbamazepine + Ponatinib Major
- Chloramphenicol + Ponatinib Major
- Clarithromycin + Ponatinib Major
- Daunorubicin + Ponatinib Major
- Deferiprone + Ponatinib Major
- Edoxaban + Ponatinib Major
- Enzalutamide + Ponatinib Major
- Eslicarbazepine + Ponatinib Major
- Imatinib + Ponatinib Major
Para assinantes do Pro+
Desbloqueie a página completa
Crie uma conta e comece um teste do Pro+ para abrir a monografia completa de Ponatinib: doses, gravidez e amamentação, efeitos adversos, advertências e todas as interações.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
Experimente o Pro+ grátis por 7 dias na web. Sem cartão.
Outros medicamentos desta classe
Perguntas frequentes
What is Ponatinib used for?
Ponatinib is a medicine in the class oncology. It is used for Acute lymphocytic leukemia, Leukemia.
What side effects have been reported with Ponatinib?
Rash and related conditions, Arthralgia, Abdominal pain, Fatigue, Headache, Constipation. Serious warning: Arterial occlusive events, including fatal MI, stroke, large cerebral artery stenosis and severe peripheral vascular disease, occurred, including in patients age 50 years or younger and without cardiovascular risk factors.
Can Ponatinib be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: no human data; in rats it caused developmental toxicity below human exposure. Avoid in pregnancy; check pregnancy status before starting and use effective contraception during treatment and for 3 weeks after. Breastfeeding: Unsafe. No milk data; it is over 99% protein bound, but its 24-hour half-life may allow build-up in the infant (LactMed). Do not breastfeed during treatment and for 1 week after the last dose (US label); NCCN also advises avoiding breastfeeding.
What does Ponatinib interact with?
MediHelp lists 114 known interactions for Ponatinib. Major: 18 · Moderate: 60 · Minor: 36. The most serious include Apalutamide, Carbamazepine, Chloramphenicol.
Monografias completas, posologia e verificador de interações no app MediHelp
Abra a referência completa, verifique interações entre vários medicamentos e use as ferramentas de posologia no app MediHelp.
